Nesfatin-1

From Wikipedia, the free encyclopedia
(A) Nesfatin-1 at 0.01 and 0.1  nanomolar stimulates glucose-dependent insulin release in vitro from MIN6 beta cells. Media with low glucose did not significantly alter insulin release between nesfatin-1-treated and control conditions. (B) Preproinsulin mRNA expression was up-regulated in MIN6 beta cells treated with nesfatin-1 at 0.01 and 0.1 nM. (C) Glucose stimulates nesfatin-1 release from MIN6 beta cells in vitro during 1 h incubation.

Nesfatin-1 is a naturally occurring protein molecule produced by the brains of mammals. It is responsible for regulating appetite and production of body fat.[1] Excess nesfatin-1 in the brain leads to a loss of appetite, less frequent hunger, a 'sense of fullness', and a drop in body fat and weight. A lack of nesfatin-1 in the brain leads to an increase of appetite, more frequent episodes of hunger, an increase of body fat and weight, and the inability to 'feel full.' The opposite condition can be artificially induced by injecting an anti-nesfatin-1 antibody into the brain.

Dr. Suraj Unniappan, Associate Professor at University of Saskatchewan's Western College of Veterinary Medicine, has studied the metabolic effects of nesfatin-1 in the brains of mammals. His studies found that rats administered with nesfatin-1 ate less, used more stored fat and became more active. Nesfatin-1-induced inhibition of feeding may be mediated through the inhibition of anorexigenic neurons.[2] In addition, the protein stimulated insulin secretion from the pancreatic beta cells of both rats and mice.[3]

The receptors within the brain are not completely understood, although they are thought to be contained in the hypothalamus and also in the solitary nucleus, where nesfatin-1 is believed to be produced via peroxisome proliferator-activated receptors (PPARs). Through observation, it appears there is some unknown relationship between nesfatin-1 and cannaboid receptors; however, its precise mechanism and effect remains controversial.[citation needed]

Nesfatin-1 was discovered in 2006 by Japanese scientists. The discovery was assisted by Hiroyuki Shimizu at Gunma University Graduate School of Medicine within the Medicine and Molecular Science Department with assistance by research conducted at Saitama University (Saitama, Japan) and the Nippon Medical College (Tokyo, Japan).

Biochemistry

Amino acid sequence of human NEFA/nucleobindin2 (NUCN2)

Nesfatin-1 is a metabolic polypeptide encoded in the N-terminal region of the protein precursor, Nucleobindin2 (NUCB2). Recombinant human Nesfatin-1 is a 9.7 kDa protein containing 82 amino acid residues.[4] Originally identified as a hypothalamic neuropeptide, Nesfatin-1 is also expressed in other areas of the brain, and in pancreatic islets of Langerhans, gastric endocrine cells and adipocytes. Nesfatin-1 plays a role in hunger and energy regulation in an independent manner.

Satiety

Studies done [5] on Wistar rats who received an intercerebroventricular injection of nesfatin/NUCB2, resulted in reduction of food consumption. This finding was also associated with the manner of dose dependency to which the rats were given. While injection of an antibody blocking nesfatin-1 increases appetite.

Nesfatin/NUCB2 is expressed in the appetite-control hypothalamic nuclei such as paraventricular nucleus (PVN), arcuate nucleus (ARC), supraoptic nucleus (SON) of hypothalamus, lateral hypothalamic area (LHA), and zona incerta in rats. Nesfatin-1 immunoreactivity was also found in the brainstem nuclei such as nucleus of the solitary tract (NTS) and dorsal nucleus of vagus.

Nesfatin/NUCB2 mRNA is selectively decreased in the PVN under starved conditions, and re-feeding restored the reduction of nesfatin/NUCB2 expression in the PVN. However, no significant changes by starvation were observed in other hypothalamic nuclei. I.c.v. injection of nesfatin-1 decreases food intake in a dose-dependent manner, whereas injection of only an antibody neutralizing nesfatin-1 stimulates appetite.

Brain

Nesfatin-1 can cross the blood–brain barrier without saturation.[6] There is a possibility that both endogenous and peripherally administered exogenous nesfatin-1 can reach the brain, and inhibit feeding behavior.

The receptors within the brain are not completely understood, although they are thought to be contained in the hypothalamus and in the solitary nucleus, where nesfatin-1 is believed to be produced via peroxisome proliferator-activated receptors (PPARs). Through observation, it appears there is also some unknown relationship between nesfatin-1 and cannaboid receptors; however, its precise mechanism and effect remain controversial.[citation needed] Nesfatin-1-induced inhibition of feeding may be mediated through the inhibition of orexigenic NPY neurons.

Nesfatin/NUCB2 expression has been reported to be modulated by starvation and re-feeding in the Paraventricular Nucleus (PVN) and supraoptic nucleus SON of the brain. Nesfatin-1 influences the excitability of a large proportion of different subpopulations of neurons located in the PVN. It is also reported that magnocellular oxytocin neurons are activated during feeding, and i.c.v. infusion of oxytocin antagonist increases food intake, indicating a possible role of oxytocin in the regulation of feeding behavior. In addition, it is proposed that feeding-activated nesfatin-1 neurons in the PVN and SON could play an important role in the postprandial regulation of feeding behavior and energy homeostasis.[7][8]

Nesfatin-1 immunopositive neurons are also located in the arcuate nucleus (ARC). Nesfatin-1 immunoreactive neurons in the ARC are activated by simultaneous injection of ghrelin and desacyl ghrelin, nesfatin-1 may be involved in the desacyl ghrelin-induced inhibition of the orexigenic effect of peripherally administered ghrelin in freely fed rat.

Nesfatin-1 was co-expressed with melanin concentrating hormone (MCH) in tuberal hypothalamic neurons. Nesfatin-1 co-expressed in MCH neurons may play a complex role not only in the regulation of food intake, but also in other essential integrative brain functions involving MCH signaling, ranging from autonomic regulation, stress, mood, cognition to sleep (A new anorexigenic protein, nesfatin-1)

Metabolism

Dual regulation of TSC mTOR S6Kinase pathway by AMPK and insulin PI3K signaling. Potential role in insulin sensitivity and the risk for obesity and type 2 diabetes. The activity of the TSC-mTOR-S6Kinase pathway is the product of the integration of signals activating the PI3K/Akt signaling (e.g., insulin) and activating the AMPK pathway (e.g., exercise, leptin, adiponectin, or hypoxia).

Japanese scientists discovered in 2006 that it is responsible for regulating appetite and production of body fat. Excess nesfatin-1 in the brain leads to a loss of appetite, less frequent hunger, a 'sense of fullness', and a drop in body fat and weight. A lack of nesfatin-1 in the brain leads to an increase of appetite, more frequent episodes of hunger, an increase of body fat and weight, and the inability to 'feel full.' This latter condition can be artificially induced by injecting an anti-nesfatin-1 antibody into the brain.

There is growing evidence that nesfatin-1 may play an important role in the regulation of food intake and glucose homeostasis.[9] For instance, continuous infusion of nesfatin-1 into the third brain ventricle significantly decreased food intake and body weight gain in rats. In previous studies, we have also shown that plasma nesfatin-1 levels were elevated in patients with type 2 diabetes mellitus (T2DM) and associated with BMI, plasma insulin, and the homeostasis model assessment of insulin resistance.[10][11]

It was found that central nesfatin-1 resulted in a marked suppression of hepatic PEPCK mRNA and protein levels in both standard diet (SD) and high fat diet (HFD) rats but failed to alter glucose 6-phosphatase (G-6-Pase) activity and protein expression. Central nesfatin-1 appeared to antagonize the effect of HFD on increasing PEPCK gene expression in vivo. In agreement with decreasing PEPCK gene expression, central nesfatin-1 also resulted in a reduced PEPCK enzyme activity, further confirming that it affected PEPCK rather than G-6-Pase.[11]

The part of the glucose entering the liver is phosphorylated by glucokinase and then dephosphorylated by G-6-Pase. This futile cycle between glucokinase and G-6-Pase is named glucose cycling, and it accounts for the difference between the total flux through G-6-Pase and glucose production. G-6-Pase catalyzes the last step in both gluconeogenesis and glycogenolysis, and PEPCK is responsible only for gluconeogenesis. In this study, central nesfatin-1 led to a marked suppression of hepatic PEPCK protein and activity, but failed to alter hepatic G-6-Pase activity, suggesting that PEPCK may be more sensitive to short-term central nesfatin-1 exposure than G-6-Pase. In addition, we also considered that the suppression of HGP by central nesfatin-1 was dependent on an inhibition of the substrate flux through G-6-Pase and not on a decrease in the amount of G-6-Pase enzyme. Thus, in SD and HFD rats, central nesfatin-1 may have decreased glucose production mainly via decreasing gluconeogenesis and PEPCK activity.[11]

Recently, it has been reported that ICV nesfatin-1 produced a dose-dependent delay of gastric emptying.[11][12]

To further delineate the mechanism by which central nesfatin-1 modulates glucose homeostasis, we assessed the effects of central nesfatin-1 on the phosphorylation of several proteins in the InsR → IRS-1 → AMPK → Akt signaling cascade in the liver. We found that central nesfatin-1 significantly augmented InsR and IRS-1 tyrosine phosphorylation. These results demonstrated that central nesfatin-1 in both SD and HFD rats resulted in a stimulation of liver insulin signaling that could account for the increased insulin sensitivity and improving glucose metabolism.[11]

AMPK is a key regulator of both lipid and glucose metabolism. It has been referred to as a metabolic master switch, because its activity is regulated by the energy status of the cell. In this study, we demonstrate that central nesfatin-1 resulted in increased phosphorylation of AMPK accompanied by a marked suppression of hepatic PEPCK activity, mRNA, and protein levels in both SD and HFD rats. Notably, central nesfatin-1 appears to prevent the obesity-driven decrease in phospho-AMPK levels in HFD-fed rats. Because hepatic AMPK controls glucose homeostasis mainly through the inhibition of gluconeogenic gene expression and glucose production, the suppressive effect of central nesfatin-1 on the HGP (Hepatic Glucose Production) can be attributed partly to its ability to suppress the expression of PEPCK mRNA and protein through AMPK activation. Furthermore, the activation of AMPK has been shown to enhance glucose uptake in skeletal muscle. Therefore, increased AMPK phosphorylation by central nesfatin-1 may also have been responsible for the improved glucose uptake in muscle.[11]

Akt is a key effector of insulin-induced inhibition of HGP and stimulation of muscle glucose uptake. We therefore examined the effects of central nesfatin-1 on Akt phosphorylation in vivo. We found that central nesfatin-1 produced a pronounced increase in insulin-mediated phosphorylation of Akt in the liver of HFD-fed rats. This increase was paralleled by an increase in muscle glucose uptake and inhibition of HGP. This provided correlative evidence that Akt activation may be involved in nesfatin-1 signaling and its effects on glucose homeostasis and insulin sensitivity.[11]

The mTOR pathway has emerged as a molecular mediator of insulin resistance, which can be activated by both insulin and nutrients. It is needed to fully activate AKT and consists of two discrete protein complexes, TORC1 and TORC2, only one of which, TORC1, binds rapamycin. In addition to mTOR, the TORC2 complex contains rictor, mLST8, and SIN1 and regulates insulin action and Akt phosphorylation. Thus, mTOR sits at a critical juncture between insulin and nutrient signaling, making it important both for insulin signaling downstream from Akt and for nutrient sensing. Until now, it has not been known whether nesfatin-1 affects activation of mTOR. To gain further insight into the mechanism underlying the insulin-sensitizing effects of ICV nesfatin-1, we assessed mTOR and TORC2 phosphorylation in liver samples of SD- and HFD-fed animals. Both mTOR and TORC2 phosphorylations were increased in livers from these rats, demonstrating activation of mTOR and TORC2 by central nesfatin-1 in vivo. As mTOR kinase activity is required for Akt phosphorylation, the observed increased Akt phosphorylation may have been caused by the concomitant activation of the mTOR/TORC2. Thus, it's postulated that the mTOR/TORC2 plays a role as a negative-feedback mechanism in the regulation of metabolism and insulin sensitivity mediated by central nesfatin-1.[11]

See also

References

  1. ↑ Oh-i, Shinsuke; Shimizu, Hiroyuki; Satoh, Tetsurou; Okada, Shuichi; Adachi, Sachika; Inoue, Kinji; Eguchi, Hiroshi; Yamamoto, Masanori et al. (2006). "Identification of nesfatin-1 as a satiety molecule in the hypothalamus". Nature 443 (7112): 709–12. doi:10.1038/nature05162. PMID 17036007. 
  2. ↑ Price, Christopher J.; Samson, Willis K.; Ferguson, Alastair V. (2008). "Nesfatin-1 inhibits NPY neurons in the arcuate nucleus". Brain Research 1230: 99–106. doi:10.1016/j.brainres.2008.06.084. PMC 2590930. PMID 18625211. 
  3. ↑ Gonzalez, R.; Reingold, B. K.; Gao, X.; Gaidhu, M. P.; Tsushima, R.; Unniappan, S. (2011). "Nesfatin-1 Exerts a Direct, Glucose-Dependent Insulinotropic Action on Mouse Islet Beta and MIN6 Cells". Journal of Endocrinology. doi:10.1530/JOE-10-0492. Lay summary – News-Medical.Net (August 10, 2011). 
  4. ↑ ProSci inc. "Nesfatin-1 Recombinant Protein". Retrieved 21 March 2013. 
  5. ↑ Shimizu, Hiroyuki; Oh-i, Sinsuke; Okada, Shuichi; Mori, Masatomo (2009). "Nesfatin-1: An Overview and Future Clinical Application". Endocrine Journal 56 (4): 537–43. doi:10.1507/endocrj.K09E-117. PMID 19461159. 
  6. ↑ Pan, Weihong; Hsuchou, Hung; Kastin, Abba J. (2007). "Nesfatin-1 crosses the blood–brain barrier without saturation". Peptides 28 (11): 2223–8. doi:10.1016/j.peptides.2007.09.005. PMID 17950952. 
  7. ↑ Stengel, A.; Tache, Y. (2011). "Minireview: Nesfatin-1--An Emerging New Player in the Brain-Gut, Endocrine, and Metabolic Axis". Endocrinology 152 (11): 4033–8. doi:10.1210/en.2011-1500. PMC 3199002. PMID 21862618. 
  8. ↑ Maejima, Yuko; Sedbazar, Udval; Suyama, Shigetomo; Kohno, Daisuke; Onaka, Tatsushi; Takano, Eisuke; Yoshida, Natsu; Koike, Masato et al. (2009). "Nesfatin-1-Regulated Oxytocinergic Signaling in the Paraventricular Nucleus Causes Anorexia through a Leptin-Independent Melanocortin Pathway". Cell Metabolism 10 (5): 355–65. doi:10.1016/j.cmet.2009.09.002. PMID 19883614. 
  9. ↑ Shimizu, H.; Oh-i, S.; Hashimoto, K.; Nakata, M.; Yamamoto, S.; Yoshida, N.; Eguchi, H.; Kato, I. et al. (2008). "Peripheral Administration of Nesfatin-1 Reduces Food Intake in Mice: The Leptin-Independent Mechanism". Endocrinology 150 (2): 662–71. doi:10.1210/en.2008-0598. PMID 19176321. 
  10. ↑ Zhang, Z.; Li, L.; Yang, M.; Liu, H.; Boden, G.; Yang, G. (2011). "Increased Plasma Levels of Nesfatin-1 in Patients with Newly Diagnosed Type 2 Diabetes Mellitus". Experimental and Clinical Endocrinology & Diabetes 120 (2): 91. doi:10.1055/s-0031-1286339. 
  11. ↑ 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 Yang, M.; Zhang, Z.; Wang, C.; Li, K.; Li, S.; Boden, G.; Li, L.; Yang, G. (2012). "Nesfatin-1 Action in the Brain Increases Insulin Sensitivity Through Akt/AMPK/TORC2 Pathway in Diet-Induced Insulin Resistance". Diabetes 61 (8): 1959–68. doi:10.2337/db11-1755. PMC 3402309. PMID 22688332. 
  12. ↑ Stengel, A.; Goebel, M.; Wang, L.; Rivier, J.; Kobelt, P.; Monnikes, H.; Lambrecht, N. W. G.; Tache, Y. (2009). "Central Nesfatin-1 Reduces Dark-Phase Food Intake and Gastric Emptying in Rats: Differential Role of Corticotropin-Releasing Factor2 Receptor". Endocrinology 150 (11): 4911–9. doi:10.1210/en.2009-0578. PMC 2775975. PMID 19797401. 

External links

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.